TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04204070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuro
Description: A research coordinator recorded the depth of the EDS from skin, the number of attempts to perform the epidural anesthesia, the repositioning of the epidural needle either in the same space or in different space, the time taken for space localisation (it is defined as time taken in seconds from skin puncture until the successful space localisation).the total time of the procedure ( time measured from the patient is fully draped and in the proper sitting position till the end of insertion of the epidural catheter ) Any complications such as paresthesia during catheter insertion, dural puncture, blood in catheter and root irritation will be recorded
Study: NCT02983604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15.
Study: NCT02882256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Description: Discharge instructions provided in video form
Study: NCT04081805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro Ablative Radiofrequency
Description: Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene
Description: The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
Study: NCT03696329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine Tablets 25 mg
Study: NCT00818545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER4017 (hydroxypropyltetrahydropyrantriol)
Description: Cream, 10%, each day during 3 months
Study: NCT03696329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrabenazine Tablets 25 mg
Study: NCT04204070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APAD
Description: APAD
Study: NCT00878436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study: NCT04130737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TORUS Stent Graft System
Description: The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
Study: NCT00002805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cladribine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT00818545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03406494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early multicomponent physical therapy program
Description: 1. Positioning (upright bed standing; turning, moving on bed).~2. Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~3. Respiratory muscle training (supine abdominal breathing training).~4. Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~5. Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage).
Study: NCT00268905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 + carboplatin AUC 5
Description: Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m\^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389 + carboplatin AUC 6
Description: After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389+carboplatin AUC 6
Description: In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
Study: NCT03375463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT00002805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Study: NCT03375463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered IV
Study: NCT00758784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromfenac ophthalmic solution 0.06%
Description: bromfenac ophthalmic solution 0.06% bilaterally twice a day
Study: NCT01055509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
Study: NCT04963829

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration
Description: It is a gel that was used in chronic ulcers healing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase ointment
Description: Participants who were subjected to a standardized treatment (collagenase ointment)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gel with 10% peel powder of unripe banana
Description: Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
Study: NCT02452164

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teaching

Intervention type: DEVICE
Group type: OTHER
Intervention: (CellScopeOTO)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (CellScopeOTO)
Study: NCT00171886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study: NCT04025450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+VRD
Description: Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VRD
Description: Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
Study: NCT03555747

Intervention type: OTHER
Group type: OTHER
Intervention: Canine distalization
Description: GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)

Intervention type: OTHER
Group type: OTHER
Intervention: Canine distalization
Description: GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
Study: NCT02566928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Description: Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine wash
Description: Index patients and consenting household members will daily daily for five days with chlorhexidine wash.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hygiene protocol
Description: Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
Study: NCT00272597

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: See Detailed Description.
Study: NCT02380807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross Tape Therapy
Description: The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
Study: NCT03548675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCA treatment
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA treatment
Description: All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
Study: NCT02170922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS solution
Study: NCT00456703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative fluid management
Description: fluid restriction
Study: NCT03163680

Intervention type: DRUG
Intervention: Omeprazole 40 MG
Description: Omperazole 40 mg twice daily
Study: NCT00456703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid restriction
Description: restriction of fluids
Study: NCT02822326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T2 Cells
Study: NCT01513174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
Study: NCT05596279

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Description: Hybrid IVUS-OCT and control IVUS were performed after stenting

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Hybrid IVUS-OCT and control OCT were performed after stenting
Study: NCT01139047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole 1% gel
Description: Apply topically once daily on one side of the face for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelaic acid 15% gel
Description: Apply topically twice daily on the opposite side of the face for three weeks
Study: NCT02225314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness
Description: Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InSight
Description: InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
Study: NCT01848938

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone treatment with PFMT
Description: A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
Study: NCT04039594

Intervention type: DEVICE
Intervention: VA ECMO
Description: VA ECMO for cardiopulmonary support
Study: NCT03154645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: a diuretic
Study: NCT00449592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Oral Zincol 1 Tab TID from day -6/-7 until discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo 1 Tab TID from day -6/-7 until discharge
Study: NCT01828528

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: An intra-operative liver biopsy was performed in 20 patients
Study: NCT01746485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C
Study: NCT00002805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT04456231

Intervention type: DRUG
Intervention: Plenvu
Description: Patients will receive Plenvu for preparation of endoscopy

Intervention type: DRUG
Intervention: Plenvu
Description: Patients will receive Plenvu for preparation of endoscopy
Study: NCT03504943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Intradialytic Exercise
Description: Timing of intradialytic exercise first half of HD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late Intradialytic Exercise
Description: Timing of intradialytic exercise second half of HD
Study: NCT02837081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective audit strategy of antimicrobial stewardship
Description: applying prospective audit as a different strategy of antimicrobial stewardship

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preauthorization strategy of antimicrobial stewardship
Description: applying preauthorization as one strategy of antimicrobial stewardship
Study: NCT04744376

Intervention type: OTHER
Intervention: QoR15
Description: Quality of Recovery 15 questionnaire (QoR-15) is a measurement tool that evaluates the recovery quality of patients after surgery and anesthesia by the patient himself.

Intervention type: OTHER
Intervention: ACS risk calculator
Description: American College of Surgeons risk calculator is a risk prediction tool for abdominal surgery. It calculates the risk of possible postoperative complications according to the type of surgery, ASA score, and patients' preoperative co-morbidities.

Intervention type: OTHER
Intervention: Clavien - Dindo classification
Description: It is a classification for postoperative complications.
Study: NCT03093584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular acupuncture with indwelling fixed auricular acupuncture needles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Expressive writing is a standard psychological method in treatment of exam anxiety
Study: NCT03678870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Education Handout
Description: a single page handout with information about how to use medications for pain after discharge.
Study: NCT03177629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment : H. pylori eradication
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment : H. pylori eradication
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO
Study: NCT00729846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verteporfin photodynamic therapy reduced fluence
Description: Patients will receive combination verteporfin photodynamic therapy with stand fluence \[600mW/cm2\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verteporfin photodynamic therapy standardfluence
Description: Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\].
Study: NCT01943474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath IV Catheter Device
Description: Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV Catheter Device
Description: Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
Study: NCT00469170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravaginal ring
Description: silicone elastomer intravaginal ring containing no drug product

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravaginal ring
Description: silicone elastomer intravaginal ring containing no drug product
Study: NCT03444532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise and cognitive-behavioral therapy
Description: 12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy